|
23 Jun 2020 |
Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II
|
|
23 Jun 2020 |
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
|
|
22 Jun 2020 |
SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II
|
|
18 Jun 2020 |
Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity
|
|
18 Jun 2020 |
Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus
|
|
18 Jun 2020 |
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
|
|
18 Jun 2020 |
Agalsidase Beta BS I.V. Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in Molecular Genetics and Metabolism
|
|
16 Jun 2020 |
FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin
|
|
15 Jun 2020 |
Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise
|
|
15 Jun 2020 |
Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin
|
|
15 Jun 2020 |
Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial
|
|
13 Jun 2020 |
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
|
|
13 Jun 2020 |
Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme
|
|
13 Jun 2020 |
Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects
|
|
12 Jun 2020 |
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
|
|
12 Jun 2020 |
Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
|
|
11 Jun 2020 |
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting
|
|
11 Jun 2020 |
FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
|
|
09 Jun 2020 |
First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial
|
|
05 Jun 2020 |
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
|
|
05 Jun 2020 |
Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial
|
|
02 Jun 2020 |
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
|
|
01 Jun 2020 |
Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia
|
|
01 Jun 2020 |
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine
|
|
01 Jun 2020 |
Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®
|
